company background image
IPSE.Y logo

Ipsen OTCPK:IPSE.Y Stock Report

Last Price

US$31.14

Market Cap

US$10.3b

7D

5.8%

1Y

-5.3%

Updated

20 Sep, 2024

Data

Company Financials +

IPSE.Y Stock Overview

Operates as a biopharmaceutical company worldwide.

IPSE.Y fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends4/6

Ipsen S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price€31.14
52 Week High€34.06
52 Week Low€26.97
Beta0.60
11 Month Change4.27%
3 Month Change1.63%
1 Year Change-5.35%
33 Year Change26.69%
5 Year Change31.34%
Change since IPO72.26%

Recent News & Updates

Recent updates

Shareholder Returns

IPSE.YUS PharmaceuticalsUS Market
7D5.8%-0.1%2.6%
1Y-5.3%21.2%30.5%

Return vs Industry: IPSE.Y underperformed the US Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: IPSE.Y underperformed the US Market which returned 30.5% over the past year.

Price Volatility

Is IPSE.Y's price volatile compared to industry and market?
IPSE.Y volatility
IPSE.Y Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: IPSE.Y has not had significant price volatility in the past 3 months.

Volatility Over Time: IPSE.Y's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPSE.Y fundamental statistics
Market capUS$10.29b
Earnings (TTM)US$740.63m
Revenue (TTM)US$3.83b

13.9x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPSE.Y income statement (TTM)
Revenue€3.44b
Cost of Revenue€618.00m
Gross Profit€2.82b
Other Expenses€2.15b
Earnings€663.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)8.04
Gross Margin82.01%
Net Profit Margin19.33%
Debt/Equity Ratio9.6%

How did IPSE.Y perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

15%

Payout Ratio